Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

NCT02041234 · Completed

Last updated 2026-05-28

This clinical trial is testing whether Roux-en-Y gastric bypass surgery helps people with type 2 diabetes and a BMI between 27 and 32 better control their blood sugar compared to standard medical treatment.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 40 people Planned (estimated).

Who can join Ages 21–65 · all sexes

Timeline Started 2014-02 · est. completion 2022-06

Where 1 site · Singapore

What this study is testing ClinicalTrials.gov NCT02041234 ↗

Description as written by the study sponsor.

Investigators aim to show that Roux-en-Y Gastric Bypass (RYGB) is superior to best medical treatment in reaching well-defined treatment end points in Asian subjects of BMI 27-32 with type 2 Diabetes (DM2). Investigators also hope to show that successful RYGB will reduce resource utilization in the near term with similar projected reduction over the medium to long term.

Treatments tested

Roux-en-Y Gastric Bypass (RYGB) Procedure

Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
Incretin analogues also known as Liraglutide Drug

Incretin analogues: Liraglutide up to 1.8 mg daily
Xenical also known as Orlistat Drug

Xenical: Up to 120 mg tds
SGLT2 inhibitors also known as Empagliflozin, Canagliflozin Drug

SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily
DPP-4 Inhibitors also known as Sitagliptin, Linagliptin Drug

Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily

Main thing measured	Number of subjects achieving HBA1c of 6% without diabetic medication
Sponsor	Khoo Teck Puat Hospital
Conditions studied	Type II Diabetes in Subjects BMI 27 to 32
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02041234 ↗